Inovio Pharmaceuticals Inc
INO
Get informed when a big investor buys or sells
+ FollowMarket Cap$58.95M
Close$
$0.07
93.3% downside
Current Fair Value
93.3% downsideOvervalued by 93.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $58.95 Million |
|---|---|
| Enterprise Value | $-17,511,860,150.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.81 |
| Beta | 1.49 |
| Outstanding Shares | 691,019,000 |
Return
| Return on Equity | -1399.93% |
|---|---|
| Return on Assets | -170.65% |
| Return on Invested Capital | -732.44% |
Valuation & Multiples
| P/E Ratio | -8.95 |
|---|---|
| PEG | 8.96 |
| Price to Sales | -1.1 |
| Price to Book Ratio | 0.14 |
| Enterprise Value to Revenue | 267999.02 |
| Enterprise Value to EBIT | 0.2 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.5 |
| Debt to Equity | 1.43 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$333,333
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$533,333
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5542▲ 42.20% |
|---|---|
| Total Calls | 429,090▼ 33.82% |
| Total Puts | 237,800▲ 177.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.69%▼ 56.62% |
|---|---|
| Total Invested | $54.59M▼ 5.04% |
| Investors Holding | 1070% |
ESG Score
No data
About Inovio Pharmaceuticals Inc
CEO: Jong Kim